. home.aspx



Novartis Gilenya staves off generic challengers⁠-for now-after federal injunction

June 25, 2019 / Kyle Blankenship

Novartis multiple sclerosis med Gilenya is facing U.S. generic challengers on all sides to its blockbuster sales, and the company hoped a court order could stave them off. The Swiss drugmaker got what it asked for—and it might just keep the med at the top of Novartis’ bestseller list, at least for now. A suite of Gilenya competitors, including Mylan, Dr. Reddy’s Laboratories and Aurobindo Pharma, have been barred from immediately launching generic versions of the drug after a U.S. district judge in Delaware issued a temporary injunction Monday at Novartis’ request. The judge, Leonard P. Stark, said allowing the generics to launch would compromise Gilenya’s ongoing patent litigation in federal court and potentially cost Novartis its $1.71 billion U.S. market share before a decision is reached. “After what might be as long as a year of generic competition by the time we get to trial and I get a post-trial opinion done, Novartis will not be able to rais...